Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for ABT and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ABT and 80,000+ other tickers.
See exactly how ABT's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ABT and 80,000+ other tickers.
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm…
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and Abbott Laboratories (NYSE:ABT) both recently posted earnings that show two healthcare giants moving in opposite strategic directions.
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Andra AP fonden lowered its position in shares of Abbott Laboratories (NYSE: ABT) by 36.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 206,708 shares of the healthcare product maker's stock after selling 118,500 shares during the quarter.
AlTi Global Inc. lowered its stake in shares of Abbott Laboratories (NYSE: ABT) by 54.7% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,563 shares of the healthcare product maker's stock after selling 12,779 shares during the period. AlTi
Ascent Wealth Partners LLC reduced its stake in Abbott Laboratories (NYSE: ABT) by 29.4% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 65,255 shares of the healthcare product maker's stock after selling 27,145 shares during the quarter. Ascent Wealth